Currently Viewing:
Newsroom
Currently Reading
Polypharmacy Plays a Role in Patients With Relapsing-Remitting Multiple Sclerosis
February 17, 2019 – Laura Joszt
Review Find Moderate Evidence That Aerobic Exercise Lowers Number of Migraine Days
February 16, 2019 – Jaime Rosenberg
Continuous Fingolimod Treatment Leads to 50% Reduction of ARRs
February 15, 2019 – Samantha DiGrande
CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy
February 15, 2019 – Mary Caffrey and Allison Inserro
What We're Reading: Syphilis Rates Rising; House Democrats and ACA Suit; WHO to Look at Gene Editing
February 15, 2019 – AJMC Staff
HCCI Report: Healthcare Spending Increased Even as Utilization Decreased or Stagnated
February 15, 2019 – Wallace Stephens
AJMC® in the Press, February 15, 2019
February 15, 2019 – AJMC Staff
5 Findings From the February 2019 Issue of AJMC®
February 15, 2019 – Christina Mattina
This Week in Managed Care: February 15, 2019
February 15, 2019

This Week in Managed Care: January 18, 2019

This week, the top managed care news included a new investigation into drug prices; FDA Commissioner Scott Gottlieb, MD, provided updates on how the government shutdown is impacting FDA work; research found comorbidities impede clinical trial participation for patients with cancer.


House Democrats are investigating drug prices, the government shutdown could endanger several drug launches, and a federal judge blocks a contraception rule from taking effect.

Welcome to This Week in Managed Care, I’m Laura Joszt.

Drug Pricing Probe

This week, the House Committee on Oversight and Reform launched a probe into drug pricing as well as the industry’s strategies to preserve market share, as the new Democratic Chair, Elijah Cummings of Maryland, followed up on longtime complaints about the high cost of certain biologics, as well as insulin.

The investigation began a day after The Washington Post examined rising insulin prices and patient rationing of supplies. Joslin Diabetes Center’s Robert A. Gabbay, MD, PhD, FACP, who is the editor in chief of Evidence-Based Diabetes Management™, told the Post, “It’s a very big problem. It’s a tragic barrier to care.”

The House investigation will focus on drugs that are the costliest to Medicare Part D, that are the costliest per beneficiary, or had the largest price increases over a 5-year period.

Part B Pricing Proposal

Meanwhile, an analysis of HHS’ proposed Medicare Part B drug pricing proposal finds that it would reduce costs overall, but raise out of pocket spending for some seniors. Research in JAMA Internal Medicine looked at 75 brand-name drugs with the highest Part B spending in 2016.

Based on 2018 prices, those in Medicare with the low-income subsidy would benefit if their drugs moved to Medicare Part D. But those with Medigap policies would spend at least 1,460 dollars more per year.

Shutdown Impact on FDA

As the government shutdown reached its third week, leaders in pharma worried that FDA would be forced to delay decisions for highly anticipated new drugs for diabetes, depression, multiple sclerosis, and HIV.

FDA Commissioner Scott Gottlieb, MD, took to Twitter with updates about bringing back food inspectors and keeping things moving with limited staff. But he warned that the PDUFA program, which sets deadlines for drug approvals, would run out of money if the shutdown continued.

Gottlieb Tweeted:



Contraceptive Rule

A federal judge in Philadelphia issued a nationwide injunction blocking the Trump administration rule that would have allowed more employers and universities to deny women access to birth control as called for under the Affordable Care Act.

The decision came a day after a California judge issued a stay on behalf of 13 states and the District of Columbia. An HHS rule issued 24 hours after Election Day let employers deny insurance coverage for contraception if they object on religious or moral grounds.

Pennsylvania Attorney General Josh Shapiro, who brought the case, said in a statement, “Families rely on the Affordable Care Act’s guarantee to afford care. . .Congress hasn’t changed that law, and the president can’t simply ignore it with an illegal rule.”

Cancer Comorbidity Challenge

Sixty percent of the patients excluded from clinical trials are left out because of a comorbidity, which has made leading cancer groups rethink who should be able to take part in a trial.

The findings, published this week in JAMA Oncology, have gained the attention of the American Society of Clinical Oncology and the FDA, since only 5% of cancer patients now take part in clinical trials. Patients are often excluded for common conditions such as diabetes, hypertension, and hearing loss.

Based on a survey of 5,500 patients who took part in a trial decision-making process, the researchers found:
  • 44% of patients without comorbidities had trial discussions, compared with 37% of patients with comorbidities.
  • Trials were offered to 21.7% of patients without comorbidities, compared with 15.7% of patients with comorbidities.
  • Trial participation took place for 11.3% of patients without comorbidities and 7.8% with comorbidities.
Modernizing criteria could let researchers include patients with organ dysfunction, prior cancer, brain tumors, and HIV.

Annual Health IT Issue

Finally, this week The American Journal of Managed Care published its annual health information technology (IT) issue, featuring articles on data breaches and telehealth.

Highlights include:
  • A study that finds hospital data breaches were followed by a 64% increase in advertising.
  • A study that shows more than half of doctors and nearly two-thirds of patients find no difference in the quality of a virtual office visit compared with an in-person visit.
  • A study that finds health information exchanges are underused by skilled nursing facilities.
Listen to a discussion with an author of the last article in the latest Managed Care Cast.

And check out the full health IT issue.

For all of us at the Managed Markets News Network, I’m Laura Joszt. Thanks for joining us.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!